Ian Clarke

Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

Stephen Schey, Paul Fields, J. Blake Bartlett et al. · Journal of Clinical Oncology · 2004 · 313 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Genotypic and Physiological Characterization of <i>Saccharomyces boulardii</i> , the Probiotic Strain of <i>Saccharomyces cerevisiae</i>

Laura C. Edwards-Ingram, Paul Gitsham, Nicola Burton et al. · Applied and Environmental Microbiology · 2007 · 202 citations · Full text

Life Sciences, Microbiology, Microbial Ecology +9

Thalidomide and its analogues have distinct and opposing effects on TNF-<i>α</i>and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells

J B Marriott, Ian Clarke, Keith Dredge et al. · Clinical & Experimental Immunology · 2002 · 155 citations · Full text

Life Sciences, Immunology, Pharmacology +14

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

J. Blake Bartlett, A Michael, Ian Clarke et al. · British Journal of Cancer · 2004 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17

Nitrogen Containing Bisphosphonates Induce Apoptosis and Inhibit the Mevalonate Pathway, Impairing Ras Membrane Localization in Prostate Cancer Cells

Grenville Oades, S G Senaratne, Ian Clarke et al. · The Journal of Urology · 2003 · 133 citations

Medicine, Oncology, Pharmacology +17